88 related articles for article (PubMed ID: 8374522)
1. High-dose cytosine arabinoside in chronic lymphocytic leukemia: a clinical and pharmacologic analysis.
Robertson LE; Hall R; Keating MJ; Estey E; Kantarjian HM; McLaughlin P; Hagemeister FB; Plunkett W
Leuk Lymphoma; 1993 May; 10(1-2):43-8. PubMed ID: 8374522
[TBL] [Abstract][Full Text] [Related]
2. Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology.
Gandhi V; Robertson LE; Keating MJ; Plunkett W
Cancer Chemother Pharmacol; 1994; 34(1):30-6. PubMed ID: 8174200
[TBL] [Abstract][Full Text] [Related]
3. Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia.
Kantarjian HM; Estey EH; Plunkett W; Keating MJ; Walters RS; Iacoboni S; McCredie KB; Freireich EJ
Am J Med; 1986 Sep; 81(3):387-94. PubMed ID: 3463209
[TBL] [Abstract][Full Text] [Related]
4. High-dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis.
Iacoboni SJ; Plunkett W; Kantarjian HM; Estey E; Keating MJ; McCredie KB; Freireich EJ
J Clin Oncol; 1986 Jul; 4(7):1079-88. PubMed ID: 3459811
[TBL] [Abstract][Full Text] [Related]
5. Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study.
Giles FJ; O'Brien SM; Santini V; Gandhi V; Plunkett W; Seymour JF; Robertson LE; Kantarjian HM; Keating MJ
Leuk Lymphoma; 1999 Dec; 36(1-2):57-65. PubMed ID: 10613450
[TBL] [Abstract][Full Text] [Related]
6. The mechanisms of Ara-C-induced apoptosis of resting B-chronic lymphocytic leukemia cells.
de Vries JF; Falkenburg JH; Willemze R; Barge RM
Haematologica; 2006 Jul; 91(7):912-9. PubMed ID: 16818278
[TBL] [Abstract][Full Text] [Related]
7. Continuous infusion high-dose cytosine arabinoside in refractory childhood leukemia.
Ochs J; Sinkule JA; Danks MK; Look AT; Bowman WP; Rivera G
J Clin Oncol; 1984 Oct; 2(10):1092-7. PubMed ID: 6593435
[TBL] [Abstract][Full Text] [Related]
8. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia.
Gandhi V; Kemena A; Keating MJ; Plunkett W
Cancer Res; 1992 Feb; 52(4):897-903. PubMed ID: 1737352
[TBL] [Abstract][Full Text] [Related]
9. High-dose cytosine arabinoside in multiple myeloma.
Kantarjian H; Dreicer R; Barlogie B; Plunkett W; Alexanian R
Eur J Cancer Clin Oncol; 1984 Feb; 20(2):227-31. PubMed ID: 6538488
[TBL] [Abstract][Full Text] [Related]
10. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
Early AP; Preisler HD; Slocum H; Rustum YM
Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
[TBL] [Abstract][Full Text] [Related]
11. Biochemical modulation of arabinosylcytosine for therapy of leukemias.
Gandhi V; Estey E; Keating MJ; Plunkett W
Leuk Lymphoma; 1993; 10 Suppl():109-14. PubMed ID: 8481660
[TBL] [Abstract][Full Text] [Related]
12. Ara-C induces apoptosis in resting B-CLL cells independent on cell proliferation, but involving Ara-CTP formation and inhibition of RNA synthesis.
Kolb JP
Haematologica; 2006 Jul; 91(7):868. PubMed ID: 16818268
[No Abstract] [Full Text] [Related]
13. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
[TBL] [Abstract][Full Text] [Related]
14. Acute tumor lysis syndrome and treatment response in patients treated for refractory chronic lymphocytic leukemia with short-course, high-dose cytosine arabinoside, cisplatin, and etoposide.
McCroskey RD; Mosher DF; Spencer CD; Prendergast E; Longo WL
Cancer; 1990 Jul; 66(2):246-50. PubMed ID: 2369709
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy for acute non-lymphocytic leukemia with low-dose cytosine arabinoside (Ara-C).
Lin SF; Liu HW; Chen TP
Nihon Ketsueki Gakkai Zasshi; 1990 Feb; 53(1):45-50. PubMed ID: 2330805
[TBL] [Abstract][Full Text] [Related]
16. Intracellular cytosine arabinoside accumulation and cytosine arabinoside triphosphate formation in leukemic blast cells is inhibited by etoposide and teniposide.
Ehninger G; Proksch B; Wanner T; Schuler U; Busch FW; Schmidt H; Schleyer E; Jaschonek K; Hiddemann W
Leukemia; 1992 Jun; 6(6):582-7. PubMed ID: 1602795
[TBL] [Abstract][Full Text] [Related]
17. High-dose cytosine arabinoside in non-Hodgkin's lymphoma.
Kantarjian H; Barlogie B; Plunkett W; Velasquez W; McLaughlin P; Riggs S; Cabanillas F
J Clin Oncol; 1983 Nov; 1(11):689-94. PubMed ID: 6366130
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group.
Avramis VI; Wiersma S; Krailo MD; Ramilo-Torno LV; Sharpe A; Liu-Mares W; Kowck R; Reaman GH; Sato JK
Clin Cancer Res; 1998 Jan; 4(1):45-52. PubMed ID: 9516951
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic parameters of 1-beta-D-arabinofuranosylcytosine (ara-C) and their relationship to intracellular metabolism of ara-C, toxicity, and response of patients with acute nonlymphocytic leukemia treated with conventional and high-dose ara-C.
Rustum YM; Riva C; Preisler HD
Semin Oncol; 1987 Jun; 14(2 Suppl 1):141-8. PubMed ID: 3589689
[No Abstract] [Full Text] [Related]
20. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
Kornblau SM; Gandhi V; Andreeff HM; Beran M; Kantarjian HM; Koller CA; O'Brien S; Plunkett W; Estey E
Leukemia; 1996 Oct; 10(10):1563-9. PubMed ID: 8847890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
